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Abstract
Graft vascularization is a crucial step to obtain stable normoglycemia in pancreatic islet transplantation. Endothelial
progenitor cells (EPCs) contribute to neoangiogenesis and to the revascularization process during ischaemic events and play
a key role in the response to pancreatic islet injury. In this work we co-transplanted EPCs and islets in the portal vein of
chemically-induced diabetic rats to restore islet vascularization and to improve graft survival. Syngenic islets were
transplanted, either alone or with EPCs derived from green fluorescent protein (GFP) transgenic rats, into the portal vein of
streptozotocin-induced diabetic rats. Blood glucose levels were monitored and intraperitoneal glucose tolerance tests were
performed. Real time-PCR was carried out to evaluate the gene expression of angiogenic factors. Diabetic-induced rats
showed long-lasting (6 months) normoglycemia upon co-transplantation of syngenic islets and EPCs. After 3–5 days from
transplantation, hyperglycaemic levels dropped to normal values and lasted unmodified as long as they were checked.
Further, glucose tolerance tests revealed the animals’ ability to produce insulin on-demand as indexed by a prompt
response in blood glucose clearance. Graft neovascularization was evaluated by immunohistochemistry: for the first time
the measure of endothelial thickness revealed a donor-EPC-related neovascularization supporting viable islets up to six
months after transplant. Our results highlight the importance of a newly formed viable vascular network together with
pancreatic islets to provide de novo adequate supply in order to obtain enduring normoglycemia and prevent diabetes-
related long-term health hazards.
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Introduction
Pancreatic islet transplantation is a widely accepted therapy for
the cure of insulin-dependent diabetes mellitus (IDDM) [1,2].
Compared to solid organ transplantation, it offers some advan-
tages: low invasive surgery and low incidence of peri-operative
risks. Pancreatic islets have a peculiar micro vascular system,
known as the insulo-acinar portal system [3–5], which is largely
destroyed during the isolation procedure, thus requiring rapid
revascularization to preserve its performance in the transplant. In
the whole pancreas transplantation the anastomosis of blood
vessels can lead to rapid revascularization [6], with vessel density
and oxygen tension being one and half times that of pancreatic
islets [7–12], thereby suggesting that reduced oxygen supply may
lead to impaired islet function [11–13]. After transplantation islets
receive nutrients and oxygen only by diffusion mechanisms
whatever the implantation site and after one month islets are still
not yet fully revascularized [7]. Carlsson et al. compared blood
perfusion and oxygenation of transplanted islets in three different
sites (kidney capsule, liver and spleen) showing that though the
three implantation organs differed markedly in their blood
perfusion, the islet graft blood perfusion and oxygen pressure
was similar irrespective of the implantation site. This suggests that
the intrinsic properties of the transplanted islets are more
important than the choice of the implantation site [7].
These findings highlight the need for an efficient vascular bed to
provide adequate support to the grafted islets. Patients with
diabetes are widely affected by endothelial dysfunction as well as
cardiovascular disease and an impaired angiogenic response to
ischaemic events [14]. As a consequence, the recipients’ graft loss
cannot be avoided without a suitable therapy to enhance islet
revascularization.
Several studies performed on animal models of ischaemic
diseases, (including myocardial infarction, stroke and peripheral
arterial diseases) showed that neovascularization can be attributed
PLOS ONE | www.plosone.org 1 April 2014 | Volume 9 | Issue 4 | e94783
to bone marrow (BM)-derived EPCs highlighting how EPCs can
be considered key players in the vascular system for therapeutic
potential [15–20]. The endothelium repair is assigned to resident
endothelial cells in addition to EPCs, which are circulating
precursors of adult neovasculogenesis and vascular homeostasis,
also involved in the revascularization of injured tissue and tissue
repair [21]. They are mobilised to the peripheral blood upon
stimuli, including tissue ischaemia and the local release of
cytokines and growth factors [22]. EPCs stimulate endogenous
angiogenesis by secreting a variety of angiogenic growth factors
during the wound healing process [23,24]. Thus, the whole of the
literature suggests that neovascularization around grafted islets has
a main role in graft survival and long-lasting functional recovery.
Hess et al. reported that transplantation of bone marrow-derived
ECs improved hyperglycemia in diabetic mice by contributing to
the recovery of injured b-cells and the endogenous beta cell
function [25]. Later Mathews et al. showed that EPCs are recruited
to the pancreas in response to islet injury by inducing a pancreas
neovascularization [26].
Accordingly, Kang et al. reported that rapid revascularization by
co-transplanted EPCs in nude mice yielded a better islet
engraftment and a consequent functional recovery with normo-
glycemia lasting up to 35 days [27].
Overall these results suggested that co-transplantation of
pancreatic islets and bone marrow-derived EPCs could be a
potential way to improve islet vascularization and overcome the
graft loss.
Here we show the development of a novel therapeutic approach
to restore islet vascularization after portal vein transplantation and
improvement of enduring graft survival by exploiting the
angiogeneic properties of the EPCs.
Methods
Experimental animals
Inbred male Lewis rats, weighing 275–300 g, (Charles River,
Calco, Italy) were used as donors and recipient of the grafts. The
animals were fed on standard rodent chow (Rieper, Bolzano, Italy)
and water ad lib, and were kept under a 12 h light/dark cycle.
Rats were made diabetic by streptozotocin (STZ, Sigma-Aldrich,
Milano, Italy, 65 mg/Kg i.p. injection). Blood glucose concentra-
tion was determined by means of a commercially available human
glucose meter (Stat Strip Xpress, Nova Biomedical UK). Animals
with fasting blood glucose higher than 16.7 mmol/l (.300 mg/
dL) on at least two consecutive measures were considered diabetic
while rats that remained lower than 16.7 mmol/l after 1 week
were withdrawn from the study. All the experimental procedures
were carried out with the approval of the ethical committee for
animal experimentation of the University of Pisa.
Islet isolation and culture
Pancreatic islets were isolated from rats by collagenase P (Roche
Diagnostics, Milano, Italy) perfusion [28] and purified by
continuous-density Ficoll gradient. Briefly, the pancreas was
distended by bile duct injection of 15 mL 4uC-cold 1 mg/mL
collagenase P (Roche Diagnostics) diluted in HEPES-buffered
Hank’s balanced salt solution (HBSS) (Sigma-Aldrich), and then it
was excised and minced. Islets were digested at 37uC for 20 min
under constant agitation. Islets were separated from exocrin tissue
by centrifugation on a Histopaque (Sigma-Aldrich) discontinuous
gradient, were removed from the interface of the layers, were
washed in HBSS, and finally resuspended into 10 mL of RPMI
(Eurobio, Milano, Italy) supplemented with 10% fetal calf serum
(FCS) (Eurobio), 1% L-glutamine (Eurobio), 10 mM glucose
(Sigma-Aldrich), penicillin (50 U/ml, Eurobio), streptomycin
(50 mg/ml, Eurobio), amphoterycin B (0,2 mg/ml, Eurobio) and
1% HEPES buffer (Sigma-Aldrich) in free floating culture flask.
Islets were handpicked under an inverted microscope under sterile
conditions and purity was assessed by Dithizone staining (Sigma-
Aldrich). For each graft, the total islet mass, expressed as the
150 mm diameter islet equivalent (IE) which was calculated based
on volumetric assumptions.
Pancreatic islets were incubated at 37uC (95% air and 5% CO2)
for 1–2 days before transplantation.
EPC isolation and expansion
Bone marrow was harvested from both femurs and tibias of
Lewis and Lewis LEW-Tg (EGFP) F455/Rrrc (RRRC, University
of Missoury) male rats, according to Dobson’s procedure [29].
Briefly, mononuclear cells (MNCs) were obtained by density
gradient centrifugation. Cells were then seeded in 6 well plates
coated with 1% gelatin (256106 MNC/well), cultured in EGM-2-
MV BulletKit (Lonza, Milano, Italy) complete medium, (i.e. EBM-
2 medium supplemented with 10% FBS, Hydrocortisone 0,2 ml,
hFGF-B 2 ml, VEGF 0,5 ml, R3-IGF-1 0,5 ml, Ascorbic Acid
0,5 ml, hEGF 0,5 ml, GA-1000 0,5 ml, Heparin 0,5 ml). Cells
were incubated at 37uC in a fully humidified atmosphere
containing 5% carbon dioxide. On day 4 the medium was
replaced and afterwards it was changed every 3 days. EPC
colonies appeared in cell cultures after 1 week and cells were then
identified by phase contrast microscopy (Laborlux S microscope
Leitz, Wetzlar, Germany) as circumvented monolayers of cobble-
stone-like cells.
Flow cytometry
Flow cytometric analysis was performed on cells at passage P2
using the following surface antibodies: CD45, CD11b (in order to
quantify hemopoietic–monocytic contamination), CD44, CD90,
CD31, Endothelium (AbD Serotec, UK; BD Pharmingen, San
Diego, CA, USA), CD133 (Miltenyi Biotec, Germany), CD34 (BD
Biosciences) and KDR (R&D system, MY, USA). Non-specific
fluorescence and morphologic parameters of the cells were
determined by isotype-matched mouse monoclonal antibodies
and 7-Amino-Actinomycin D (7-AAD) was used to exclude dead
cells. For GFP+ EPCs, green fluorescence intensity was assessed at
different passages in culture. The cells were acquired with a
FACSCalibur (Becton Dickinson, Milano, Italy; argon laser
source, with wave length of emission at 488 nm and power of
emission 15 mW) and data was analysed by CELL QUEST
software (Becton Dickinson).
Dil-Ac-LDL uptake
To identify ex vivo expanded EPCs, the cells were imaged for
their incorporation of acetylated low-density lipoprotein (aLDL)
labelled with fluorescent Dil dye (Dil-Ac-LDL, Invitrogen, Milano,
Italy), Endothelium FITC (AbD Serotec, UK; BD Pharmingen,
San Diego, CA, USA) and DAPI (Invitrogen). The cells were
incubated with 10 mg/ml Dil-Ac-LDL for 4 hours at 37uC on a
glass slide; subsequently, cells were washed and Endothelium was
added (10 mg/ml) for 20 min in the dark. After fixation with 10%
formalin for 20 min at 4uC, EPCs were washed and DAPI was
added following manufacturer’s instruction. Cells were visualized
by fluorescence microscopy on a Laborlux S microscope (Leitz,
Wetzlar, Germany).
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In vitro Angiogenesis assay
BD Matrigel Basement Membrane Matrix (BD, Bioscience,
Milano, Italy) was thawed on ice overnight, and a volume of
50 mL, added to EGM-2 (Lonza) supplemented with 1% FCS, was
spread evenly over each well of a 24-well plate. The plates were
incubated for 30 min at 37uC to allow the Matrigel to form a gel.
GFP+ EPCs were seeded (3.06104 cells/cm2) in darkness and
cultured in 1 ml of EGM-2 medium supplemented with 1% FCS.
After 2 hours of incubation at 37uC, phase contrast (bright field)
and fluorescence images were recorded on a Carl Zeiss
Microscope (Carl Zeiss, Milano, Italy) equipped with a fluores-
cence camera, (AxioVision 4.8.2 software). Cells were checked
approximately every 2 hours to observe the tube formation up to a
final time point of 20 hours (Figure S1).
In vivo experiments
The effect of EPC intravenous administration was assessed in a
syngenic model (from Lewis donors to Lewis recipients) of a
marginal mass pancreatic islet transplantation. Diabetic-induced
rats were transplanted into the portal vein with 700 syn-IE alone
(n = 6), 700 syn-IE plus 56105 EPCs (n = 11), or 56105 EPC
(n= 4) into the portal vein.
Portal Islet Transplantation
Five days after STZ treatment, diabetic rats were anaesthetized
(Zoletil 100: tiletamin 90 mg/Kg and zolazepam 10 mg/Kg, i.p,
Virbac, Milano, Italy) and transplanted as previously described
[30]. Freshly detached 56105 EPCs were suspended in 500 ml PBS
saline buffer solution and concomitantly mixed with 700 syn-IE
freshly isolated. The cell mix was then incubated at 37uC 5% CO2
for up to one hour by giving gentle pats to the mix holder every 15
minutes to avoid adherence to the culture plastic. 700 syn-IE alone
or 56105 EPCs plus 700 syn-IE were finally injected through a
26G needle and re-flushed 2–3 times into the portal vein of each
animal. To prevent potential experimental biases, the aliquots
from the same batch of islets were transplanted in both
experimental groups in parallel each time.
Assessment of Graft Function
Fasting blood glucose levels were used to assess islet graft
function. The measures were performed at defined time points
from transplantation. Graft failure was defined as a return to
hyperglycemia .16.7 mmol/l (300 mg/dL) by two consecutive
measurements.
Intraperitoneal glucose tolerance test (IPGTT)
Rats were given an intraperitoneal glucose tolerance test at
different time point from transplantation (15, 30 and 180 days).
After fasting overnight the animals were injected with 2 gr/Kg
body weight of glucose intraperitoneally. Blood glucose was
measured at 0, 15, 30, 60, 90, 120 and 150 minutes after injection.
These values were then compared to the control values (diabetic
and healthy rats).
Real-time PCR
Liver samples were collected to assess the mRNA expression of
all genes involved in vascularization. Since transplanted islets are
homogeneously distributed throughout the whole liver [31], a
random sampling of the tissue in six different points for each
animal was performed (not exceeding 30 mg per sample). The
experiments were run in triplicate. Total RNA extraction and
purification of EPCs/GFP+ EPCs and RNAlater-treated liver
samples of transplanted animals were carried out using the
RNeasy Mini kit (Qiagen, Hilden, Germany), according to the
manufacturer’s protocol. The On-Column DNase I enzymatic
digestion set was used to remove genomic DNA from total RNA
preparations. The amount of extracted RNA was quantified by
measuring the absorbance at l=260 nm with a Biophotometer
Plus Eppendorf (Eppendorf, Milano, Italy) spectrophotometer.
Reverse transcription of the samples was performed with
RevertAid First Strand cDNA Synthesis Kit (Fermentas, Thermo
Scientific, Milano, Italy). The VEGF-A, PECAM-1, HGF and
ANG-1gene expressions were evaluated using a SYBR Green
Master Mix technique (Qiagen), according to the manufacturer’s
instructions. Controls and samples were run in triplicate on 96-
well reaction plates with the iQ5 Multicolor Real-Time PCR
Detection System (Bio-Rad, Milano, Italy).
For all pairs of primers the following experimental run protocol
was used: denaturation program (95uC for 3 min), amplification
(95uC for 15 s, 62uC for 1 min, 40 repetitions) and quantification
program (melting curve program at 56–95uC with a heating rate
of 0.5uC per second and continuous fluorescent measurement).
Primers (see table 1) were generated according to published
protocols [32–36].
All the amplifications were carried out with normalization of
gene expression against the glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) reference gene. Estimation of gene expression
was calculated according to the 2-DDCT method using the Bio-Rad
iQ5 2.1.
Histology
Rats were transcardially perfused by 200 ml of PBS at 0uC
followed by 400 ml of 4% paraformaldehyde with a pH of 7.4.
Liver samples were post-fixed in the same solution for 12 hours at
4uC and, after washing, were transferred in a 30% sucrose solution
in PBS for cryoprotection for 2–3 days. Afterwards the liver
samples were cut in 16 mm thick slices using a cryostat (Microm
Cryo-Star HM 560). In order to detect sparse pancreatic islet in
liver samples, sections were collected in PBS and one in every six
was stained by hematoxylin and eosin (H&E). Slices were rinsed in
PBS (3610 min) and pre-incubated in 5% normal goat serum
(NGS) (Invitrogen) containing 5% bovine serum albumin (BSA)
(Sigma-Aldrich) and 0.3% Triton-X-100 (Sigma-Aldrich) in PBS
overnight at 4uC and then incubated, in various combinations,
with the following primary antibodies:
Table 1. Sequence of the primers used in Real-time PCR.
Gene Primer sequences
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1) mouse anti-PECAM-1 (TLD-3A12) (Santa Cruz Biotechnol-
ogy, Heidelberg, Germany), primary antibody (1:200),
overnight in PBS 4uC.
2) rabbit anti-insulin (Abcam, Cambridge, UK) (1:200) for
48 hours in PBS 4uC.
Secondary antibodies:
1) Donkey Alexa Fluor 594 (Invitrogen) anti mouse (1:200) for
4 hours in PBS at room temperature.
2) biotinylated anti rabbit (Vector Laboratories, Peterborough,
UK) (1:200) for 4 hours in PBS at RT and Fluorescein-
Streptavidin (Vector Laboratories) (1:200) in PBS for 4 hours
at room temperature.
All slices were washed 3610 min in PBS and covered with a
Vectashield cover-slip (Vector Laboratories). Control sections were
treated with secondary antibodies as described above, without
primary ones. Slice analysis was performed using a Leica 4D
confocal laser scanning microscope with an argon–krypton laser
(Leica, Milano, Italy). Confocal images were generated using PL
Fluotar 10X (na.0.3), 40X oil (na.1.00) and 100X oil (na.1.3).
Surface rendering was used to display and analyze the structures
creating shaded solid bodies. The rendered surfaces were
interactively displayed and analyzed for global structure properties
and interaction between stained elements. ImageJ 1.43, and
Bitplane Imaris 7.4.2 were used to visualize and count maximum
intensity, average intensity and co-localization.
Statistical analysis
Data was analyzed using GraphPad Prism version 5 software
and all numerical values were expressed as mean 6 SEM. Data
was compared using one way ANOVA followed by Tukey’s test to




EPCs isolated and expanded from BM of male Lewis and Lewis
EGFP rats were analysed by morphology, flow cytometry and Dil-
Ac-LDL uptake (Figure 1). Since wild type and GFP+ EPCs
showed comparable characteristics, data were reported as mean 6
SD of the different analysed clones. EPCs were positive for CD44,
CD90 and Endothelium (ox43 protein expressed on vascular
endothelial cells in each rat tissue), while negative for CD31,
typical of mature endothelial cells, and for hematopoietic markers,
(CD45, CD11b) (Figure 1A). We did not detect significant amount
of positive cells for CD133 (1.561.7, mean6SD), CD34 (0.6 6
0.8, mean6SD) and KDR (0.360.4 mean6SD) even though
some authors have previously reported converse results [37].
GFP+ EPCs showed a GFP expression over 94% at every passage
along with the presence of endothelial markers (data not shown).
RNA was extracted by in vitro generated EPCs to study the gene
expression of PECAM-1 (CD31), VEGF-A, ANG-1 and HGF by
real-time PCR. Data showed high expression of ANG-1 and HGF,
in contrast, a minor expression of PECAM-1 and a negligible level
of VEGF-A were observed (Figure 1B). The functional character-
ization of EPCs showed the property of the cells to uptake Dil-Ac-
LDL (Figures 1C–F). In vitro angiogenic ability of EPCs was
assessed (both in fluorescence and in bright-field) within the first
12 hours after seeding, by using an endothelial tube-formation
assay. At various time points EPCs are shown to grow into an
organized capillary network (Figure S1) and revealed a classical
cobblestone-like cell morphology (14 days from seeding)
(Figures 1G–H) [38].
Long-lasting glycaemic control in animals receiving EPCs
and islets
Based on our previous results [30] we decided to co-transplant
EPCs (56105) with a marginal mass of 700 syngenic islet
equivalent (syn-IE) into the portal vein of streptozotocin-induced
diabetic rats. The same dose of EPCs was found to be effective also
by other authors [26,27,38]. EPCs derived from GFP-transgenic
rats were used to follow the fate of these cells after their injection
and to evaluate their contribution to the formation of new vessels
in the graft. Both EPCs and GFP+ EPCs were used in association
with pancreatic islets to perform transplants; since glycaemic
curves were comparable without significant differences in blood
glucose levels, all data were grouped and plotted together. Blood
glucose levels of transplanted animals were monitored for up to 6
months. The syngenic transplantation of 700 syn-IE alone (n= 5)
induced a fast decrease in blood glucose levels, which raised to
high values within twelve days of observation. A gradual
recurrence of diabetic levels was observed up to day 15
(Figure 2A). Co-transplantation of 700 syn-IE and 500,000 EPCs
(n= 11) showed a faster decrease in blood glucose levels compared
to animals receiving 700 syn-IE alone and the values remained
under the diabetic threshold throughout the whole observation
time (p,0,0001 Figures 2A and B). In contrast, administration of a
single dose of 500,000 EPCs alone (n= 4) did not affect glycemia of
transplanted animals (Figure 2A). Although a minor decrease in
blood glucose levels was observed at day 3, the change was not
significant. The animals receiving EPCs or 700 syn-IE alone were
monitored for 30 days after transplantation to confirm their
diabetic status; during this time lapse (between 15 and 30 days
after transplant) the animals appeared very weak, their body
weight decreased and we did not observe a recovery from their
diabetic status, so the animals were sacrificed (Figure 2B).
Conversely, the group of animals co-transplanted with 700 syn-
IE plus 500,000 EPCs maintained normoglycemia for 180 days.
The response was striking: blood glucose levels were under
200 mg/dl up to the sacrifice day of the animals (p,0,0001,
Figure 2B).
To evaluate islet functionality, a series of intraperitoneal glucose
tolerance tests (IPGTT) were performed at different time points
from transplantation and compared with healthy (n = 4) and
diabetic (n = 4) reference curves (Figure 2C). The glucose
clearance 15 days after transplantation showed that the decrease
of glucose concentration in animals receiving 700 syn-IE plus
500,000 EPCs was observed 30 minutes after glucose administra-
tion unlike healthy animals (15 minutes); 120 minutes later there
were no significant differences between the values. The curve
relative to the co-transplanted group showed a very significant
difference when compared with diabetic values (n = 4, p,0.001
Figure 1. Characterization of EPCs. Flow cytometric analysis of EPCs. (A) Percentage of expression of CD45, CD11b, CD90, CD44, CD31 and
Endothelium markers were shown. Each column represents mean 6 SD of six different clones. (B) mRNA levels of VEGF-A, ANG-1, PECAM-1 and HGF
in cultured EPCs (***p,0.0001 VEGF-A versus ANG-1; ***p,0.0001 VEGF-A versus HGF; ***p,0.0001 ANG-1 versus PECAM-1; *p,0.05 ANG-1 versus
HGF; ***p,0.0001 PECAM-1 versus HGF). Error bars are 6 SEM. (C-F) In vitro functionality of EPCs was identified by positive staining for endothelial
antibodies (Endothelium (C, green), Dil-Ac-LDL (D, red), nuclei (E, blue), merge (F)).(G, H) EPCs cobblestone-like morphology.
doi:10.1371/journal.pone.0094783.g001
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120 min). Neither group of animals receiving 700 syn-IE alone
(n = 4) nor EPCs alone (n= 3) showed a statistically significant
difference from the diabetic group. Glucose-clearance of co-
transplanted animals, at different time points, was compared to
values of healthy animals (15, 30, 90 days after the transplant,
Figure 2D). The trend in glucose clearance was very similar
among the studied groups and it correlated well with the long-term
control of glycaemic levels (Figure 2D).
Neoangiogenesis triggered by EPCs in engrafted islets
Livers and pancreata were excised for histological analysis to
detect viable islets and the corresponding EPC neo-vascularization
through insulin and PECAM-1 immunocytochemistry respectively
(Figure 3). Transplanted islets were easily identified in liver
samples by H&E staining and by anti-insulin immunofluorescence
from one to six months after transplant (Figures 3A and B).
PECAM-1 immunostaining, commonly used to demonstrate the
presence of endothelial cells in histological tissue sections, when
associated with the simultaneous presence of GFP+ EPCs
demonstrates the presence of newly formed vessels in the grafts
to derive blood flow from the host vessel system. In particular, in
animals at 30 days from transplant, the new vessel appeared to
emerge directly from the perilobular ones and EPC co-localization
with PECAM-1 within the islets suggested newly formed blood
vessels (Figures 3C and D). Furthermore, an average endothelial
thickness of 4.7761.1 microns one month after transplantation
(Figure 3E) reinforced the notion of a juvenile cell as wall thickness
retreats to 1.860.7 microns six months after transplant (Figure 3F),
well within typical values of mature cells.
Morphological assessment by H&E of pancreatic sections
showed that no residual islets after STZ treatment were detectable.
Comparison of the pancreatic tissue sections of wild type
(Figure 4A) and co-transplanted EPC animals (Figure 4B) showed
that islets were present only in wild type animals (black arrows),
Figure 2. Effect on the glycemic levels of cell-based treatments. Glycemic levels of 700 syn-IE + 500,000 EPCs (n = 11, red line) compared with
700 syn-IE (n = 5, black line) and with 500,000 EPCs alone (n = 4, green line). (A) Co-transplantation of 700 syn-IE+500,000 EPCs induced a faster
decrease of blood glucose levels than the other treatments (***p,0.0001, **p,0.001; *p,0.05). One way ANOVA was carried out to compare
different treatments (***p,0.001 700 syn-IE+500,000 EPCs versus 700 syn-IE; ***p,0.01 700 syn-IE+500,000 EPCs versus 500,000 EPCs alone). On day
15th, the difference between 700 syn-IE+500,000 EPCs and 700 syn-IE was extremely significant (*** p,0.001). (B) Monitoring of blood glucose levels
in the long-term showed that animals receiving 700 syn-IE+500,000 EPCs maintained normoglycemic values for the overall observation time, (6
months) compared to animals treated with 700 syn-IE alone (***p,0.001). (C) IPGTT in transplanted animals. Glucose clearance in the transplanted
groups on the 15th post transplantation day. The comparison of glucose clearance for animals receiving 700 syn-IE (black line), 500,000 EPCs alone
(green line) and 700 syn-IE+500,000 EPCs (red line) with healthy (blue line) and diabetic animals (yellow line) showed a return to normoglycemia
within 120 min since the glucose injection only for the co-transplanted and healthy groups. One way ANOVA to compare different treatments,
showed that at 60, 90, 120 and 150 min. healthy and co-transplanted groups showed no statistically significant differences, while the two groups
showed statistically significant differences compared to the diabetic group (***p,0.001). (D) Glucose clearance in the co-transplanted group at
different time points. The glucose clearance was measured at 15, 30, 90 days after transplantation for animals receiving 700 IE+500,000 EPCs. One way
ANOVA showed that the differences among the curves were not statistically significant. Error bars are +/2 SEM. One way ANOVA was performed
within each curve by comparing different time points versus day 0.
doi:10.1371/journal.pone.0094783.g002
EPC and Islet Transplantation in Chemically-Induced Diabetes
PLOS ONE | www.plosone.org 6 April 2014 | Volume 9 | Issue 4 | e94783
EPC and Islet Transplantation in Chemically-Induced Diabetes
PLOS ONE | www.plosone.org 7 April 2014 | Volume 9 | Issue 4 | e94783
while the absence of islets was evident in the the exocrine
pancreatic tissue of co-transplanted animals. Moreover by
comparing the images of liver parenchyma of wild type animals
(Figure 4 C) and animals transplanted with GFP+ EPCs and wild
type islets (Figure 4D), we did not detect lymphocytic infiltration in
the islet aggregates.
We also evaluated whether an increase in the height of the
endothelium and in the vessel density could result from EPC
infusion in our model of islet transplantation (Figure 5). Both
parameters were estimated by using stereological methods.
Animals receiving 700 syn-IE plus 500,000 EPCs were sacrificed
at different time points and were compared to both wild type
control and animals receiving 700 syn-IE alone sacrificed at 30
days post-transplant.
Statistical differences in the height of the endothelium and vessel
density were found among different groups. In particular, in co-
transplanted animals, an increase of both parameters was observed
in height (p,0.001) and density already at 15 days after
transplantation and this trend increased up to 120 days
(p,0.0001). At 180 days, the height of the epithelium was well
within control values (Figure 5A), confirming typical thickness of a
mature endothelium; on the contrary, the vessel density remained
higher than control thus strengthening the already begun
improved vascularization in accordance to a new vessel network
formation (p,0.001) (Figure 5B).
Since the vascularization of the animals receiving islets alone
(700 syn-IE) is highly compromised, the vascular epithelium
appeared disrupted and consequently the endothelial thickness
and vascular density were very low, under the control values
(endothelial thickness p,0.001, Figure 5A; vessel density p,0.05,
Figure 5B).
In vivo EPC-induced regulation of angiogeneic genes
To evaluate whether EPCs were able to modify angiogenic
response through gene expression modulation, mRNA was
extracted from the liver of transplanted animals and tested for
VEGF-A, ANG-1and PECAM-1, specific genes involved in
angiogenic response. Gene expression levels of animals trans-
planted with either 700 syn-IE alone or 700 syn-IE plus 500,000
EPCs were analyzed at different time points after transplantation
(7, 15, 30 and 180 days) and compared to the expression in healthy
controls. VEGF-A expression was maximal at day 15 from
transplantation, followed by a significantly decrease at day 30 for
both groups (Figure 6A). In relative ANG-1 mRNA expressions an
increase was observed in animals receiving 700 syn-IE compared
to the healthy group up to 30 post-transplant, (p,0.01),
(Figure 6B). In contrast, the co-transplanted group did not show
significant differences when compared to healthy controls.
PECAM-1expression showed a markedly increase between 7 and
15 post-transplantation days in the 700 syn-IE group (p = 0.003),
followed by a decrease at day 30 (Figure 6C). Conversely, the
animals receiving co-transplantation showed significant differences
compared to healthy control for the whole observation time.
Discussion
Despite intense research carried out on EPC biology in the last
10 years a consensus on the definitive appearance and function of
EPCs have not been yet reached [37]. Very little data are available
on rat EPC characterization and at present a clear definition of
EPC surface markers still remains elusive. Therefore there are
controversial results obtained in EPC therapy derived from
different EPC populations [39,40]. In vitro, two different popula-
tions of EPCs can be derived: early and late EPCs. Even if these
cells are characterized by different morphology, proliferation
potential and phenotype, in vivo these seem to improve vascular-
ization [23]. In this work we studied the effect of bone marrow-
derived rat late-EPCs in a marginal mass model of pancreatic islet
transplantation in chemically-induced diabetic rats (STZ-treated),
in an attempt to re-establish islet microvasculature destroyed
during the islet isolation procedure. In a previous work we showed
that transplantation of 700 IE in diabetic rat induced a significant
decrease in blood glucose but failed to attain normoglycemia
therefore this is considered a marginal mass model of islet
transplantation [30]. We decided to transplant only a marginal
mass of islets to overcome one of the main problems in islet
transplantation: the limited donor-islet availability [41,42]. On the
basis of our results, we suppose that in the same model of full grafts
(i.e. a transplantation of 1400 IE, [30]) the EPCs would be able to
support islet revascularization better than in the marginal mass
model. It is well known in fact that long-lasting hyperglicemia
impairs the vascular network [14] preventing the revascularization
process. In the full graft model normoglycemia is reached faster
and for a long period than in the marginal mass, thus the EPC
Figure 3. Histological assessment. Islet stained by anti-insulin antibody (magenta) respectively one month (A) and six months (B) after
transplantation. (C–D) Islet, in the centre of a liver lobule, in contact with a network of new capillaries, as suggested by a strong presence of GFP+
EPCs (yellow) and PECAM-1 (red), from a perilobular vein (*) for animals at 30 days from transplant. The 3D reconstruction (D), better explain the
previous picture (C). The islet was shown in green, while the perilobular vein was red. Orange represented the capillary network, the magenta an
arteriole and the EPCs were yellow. New formed vessel in the islets one month (E) and six months (F) after transplantation, white arrows indicated
endothelial (red) GFP+ EPCs. The endothelial cells in E exhibit a higher shape of those in F.
doi:10.1371/journal.pone.0094783.g003
Figure 4. Evaluation of pancreas and liver tissues. (A) Viable islets
in the pancreas of wild type animals as indicated by black arrows; (B)
exocrine tissue without residual islets in a pancreas section of animals
co-transplanted with GFP+ EPCs and wild type islets at 30 days after
transplant. (C) Intact hepatic parenchyma of wild type animals; (D) liver
tissue section of animals receiving GFP+ EPCs and wild type islets:
image of a pancreatic islet at 30 days after transplant. No lymphocitic
infiltration is evident.
doi:10.1371/journal.pone.0094783.g004
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efficacy in the islet revascularization could be increased. Our
results highlight that neo-vascularization is a crucial process in
promoting a viable and enduring islet pancreatic transplant in
experimental diabetes. GFP+ EPCs that lasted for 180 days after
co-transplant promoted a newly formed vascular network.
Accordingly, histological analysis revealed insulin-positive clusters
of islets surrounded by GFP-expressing newly formed endothelial
cells only in livers of recipients that received a co-transplant. This
was combined with a long-lasting normoglycemia and a modu-
lation of the expression of angiogenesis-related genes, which
accompanied a new blood vessel formation. Since we did not
detect any residual beta cell mass in pancreatic tissues of STZ-
treated animals by H&E analysis, we speculated that the role of
EPCs was to sustain the function of donor grafted islets more than
residual islets of the recipients. Our data is in accordance with
recently published results by Oh et al. They showed that not only
donor EPC co-transplanted with islets are able to improve intra-
islet microvasculature but also contribute to maintain islet
organization and morphology. Unlike us they used early EPCs
co-transplanted with a marginal mass of syngenic islets under
kidney capsule of diabetic-induced mice [43]. Impaired revascu-
larization is one of the main issues of graft failure [44] and
attempts have been made to overcome this obstacle through
administration of angiogenic factors such as VEGF [45] and/or
mesenchymal stem cells [46], or stimulation with GM-CSF to
mobilize bone marrow-derived EPCs [47]. Nevertheless angio-
geneic factors had a short half-life as consequence their use is not
free of safety concerns [48]. On the other side the migration of
mesenchymal stem cells towards the site of inflammation and their
dispersion in several organs of the recipient [49–53] reduced their
efficacy on the grafted islets and could increase the risk of tumour
development [54], even though recently a pooled analysis showed
no correlation between MSCs and malignancies [55]. GM-CSF
treatment could be appealing for its immediate clinical transla-
tional potential, on the other hand this approach might have
significant effects on the immune system of the recipient [47]. In
this context the interest towards the effect of EPCs in islet
transplantation arised; in 2004, Brissova et al. reported that in vitro
EPCs co-cultured with pancreatic islets were able to improve beta
cell survival and insulin secretion [56] and recently many works on
EPC and islet co-transplantation have been published [27,43,57].
The EPC-cotransplant method described here could be a more
physiological way of inducing neovascularization in islet trans-
plant. EPCs in fact did not disperse into the recipient but were
confined in the implantation site around the transplanted islets
thus making them safe for use in clinical settings. Overall EPCs
were found to support beta cell proliferation [56,58], cause a
threefold improvement of beta cell volume and double functional
blood vessels [57]. In addition, it has to be considered that patients
with diabetes are characterized by low levels of circulating EPCs
correlated to the impaired endothelium, so that the revasculari-
zation process is delayed upon an ischaemic insult (one week later
compared to the healthy patient) [16,59]. A re-establishment of a
complete vascular network was successfully observed in the present
study. Most importantly, the overlapping of blood glucose levels,
blood glucose control and revascularization lasting 180 days
suggests that donor EPCs may play a key role in enhancing and
maintaining revascularization over long periods of time. Many
works have also investigated the structure and function of intra-
islet endothelial cells to clarify their role in blood vessel
regeneration and in revascularization of islet graft [56,60,61].
Nyqvist et al. observed that the transplantation of freshly isolated
islets with a relevant number of endothelial cells, in contrast to
cultured islets, markedly improved their vascularization, thus a
Figure 5. Vessel morphologic parameters assessment. (A) Endothelial thickness: average height(mm 6 SEM) of the endothelial cells within the
islets of wild type animals (black column), animals receiving islets alone (700 IE) (white column) and animals receiving 700 syn-IE plus 500,000 EPCs
(IE/EPC) sacrificed at different time points (gray column)(***p,0.0001 at days 15, 30 and 120 versus control for IE/EPC group; ***p,0.0001 for 700 IE
versus control). (B) Vessel density: average number (6 SEM) of endothelial cells detected along a line in histological sections for wild-type animals,
animals receiving islets alone (700 IE) (white column) and animals receiving 700 syn-IE plus 500,000 EPCs (IE/EPC) sacrificed at different time points
(gray column) (***p,0.0001 at days 15, 30 and 120 versus control for IE/EPC group; ***p,0.0001 for 700 IE versus control).
doi:10.1371/journal.pone.0094783.g005
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preservation of intra-islet endothelial cell mass was able to improve
the long-term graft function [62]. Later the same authors further
observed that donor islet endothelial cells contributed to the
revascularization of freshly isolated islets by participating in early
processes of vessel formation; nevertheless, these cells did not
increase the vascular density or improve the endocrine function of
the grafts [63]. In our work the absence of residual islets of the
recipient in co-transplanted animals after STZ treatment supports
the hypothesis that normoglycemia is due to donor islets and
EPCs. Donor EPCs could effectively contribute to the intra-islet
EPCs to support islet function and maintain morphological
organization. Furthermore, the induced neovascularization in
the co-transplanted group by EPCs is explained by the modulation
of specific gene expression involved in the angiogenic process,
whereas this is not observed in the control group. VEGF is the
most important gene involved in the regulation of blood vessel
sprouting during development, growth and disease; in particular,
VEGF-A member is positively regulated by hypoxia [64]. Our
data show a marked increase in the VEGF-A level in liver tissues
of animals in the first 15 days after transplantation for groups
receiving both 700 syn-IE and 700 syn-IE plus EPCs. It has to be
considered that islets secrete VEGF-A after isolation, as the result
of the ischemic insult derived from it and from the culture
condition and also that in the first days after transplantation there
is an incomplete vascular network formation and only a partial
recovery in functionality. Nevertheless in the co-transplanted
group the increase in VEGF-A expression was lower than in the
group of animals receiving islet alone, due to an exogenous
administration of EPCs. Our findings are in line with data
demonstrating that the vascularization of transplanted islets is
delayed by the presence of hyperglycemia, derived from an
increase in local oxygen consumption [65]. ANG-1 is responsible
for vessel stabilization and promotion of pericytes adhesion by
tightening endothelial junctions [66]. Jeansson et al. demonstrated
that ANG-1 is not only necessary in the quiescent mature
vasculature, but it also exerts a role in the regulation of the
response to tissue injury and microvascular disease in diabetes
[67]. High levels of ANG-1 gene expression, observed in the 700
syn-IE group, suggest that islets were unable to tighten endothelial
junctions and maintain blood vessels in host diabetic environment.
On the contrary, the down-regulation of ANG-1 observed in the
co-transplanted group, is probably related to the EPC-supported
vascularization. At variance with the other genes, PECAM-1 is
involved in transendothelial migration of neutrophils, monocytes
and natural killer cells both in vitro and in vivo. Indeed
transmigration and inflammation can be significantly reduced
when antibodies directed against PECAM-1 are used [68]. The
strong down-regulation of PECAM-1 in co-transplanted group
indicates that administration of exogenous EPCs is effective also in
reducing the recruitment of immune system cells thus hampering
an inflammatory response as shown by the absence of infiltrating
mononuclear cells into the liver parenchyma. This result was
supported also by Cantaluppi et al. who demonstrated that
microvesicles, released by EPCs on human pancreatic islets,
significantly inhibited spontaneous and cytokine-induced periph-
eral blood mononuclear cell adhesion to islet endothelial cells [69].
Microvescicles expressed CD154 marker as able to bind CD40
expressed by islet endothelial cells, thus interfering with leukocyte
adhesion to endothelium. Overall our obtained results by gene
expression suggest that day 15 is the crucial time point in graft
Figure 6. Modulation of angiogenic genes. mRNA levels of
angiogenic factors in the livers of healthy animals (black bars), animals
transplanted with 700 syn-IE (white bars) or 700 syn-IE+500,000 EPCs
(grey bars) at different time points. (A) VEGF-A, ***p,0.0001 versus
healthy. Compared to the control group the 700 syn-IE alone showed
an higher increase (***p,0.0001) of VEGF-A expression than 700 syn-IE
plus 500,000 EPCs(**p,0.001). Moreover statistical significant differ-
ences were found at different time point after transplantation inside the
groups (700 syn-IE alone ***p,0.0001 day 7 versus day 15 and day 30
and ***p,0.0001 day 15 versus day 30; 700 syn-IE plus 500,000 EPCs
**p,0.001 day 15 versus day 7 and day 30 and ***p,0.0001 day 15
versus day 180. (B) In ANG-1 expression no significant differences were
found between the 700 syn-IE plus 500,000 EPCs group and healthy
while at day 30 from transplant a significant increase was found in the
700 syn-IE alone group versus healthy (*p,0.01). Furthermore at day 30
a significant difference was found between 700 syn-IE alone and 700
syn-IE plus 500,000 EPCs one (**p = 0.0014). (C) PECAM-1, **p = 0.003
versus healthy. The column of gene expression relative to the animals
treated with 700 syn-IE alone was not reported at 180 days, because the
animals died within 45 days after transplantation due to lack of
glycemic control. Error bars are +/2 SEM.
doi:10.1371/journal.pone.0094783.g006
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revascularization. Recently Kang et al. reported that human cord
blood-derived EPCs co-transplanted with porcine islets into renal
capsules of diabetic nude mice were able to induce a rapid
revascularization, a better graft perfusion and a recovery from
hypoxia [27]. Although this experimental design was similar in
some respects to our transplantation model, there were some
differences in the implantation site, the origin of both islets and
EPCs, timing of analysis and the islet dose used. To investigate the
effect of EPCs on islet vascularization either early or a long time
after transplantation, we chose a syngenic transplantation model to
avoid any other interferences due to allo- or xenograft rejection.
Moreover, the kidney subcapsular site is most commonly used in
rodent models and has good results in that diabetes is reversed
within a few days. Nevertheless, though the development of an
instant blood-mediated inflammatory reaction (IBMIR) upon
intraportal islet infusion, the progressive loss of islet function even
in recipients of autologous grafts (in humans, but also in the canine
model [70]), the portal vein implantation site still remains the gold
standard for islet transplantation in the clinical setting. Until now
the intraportal site was considered to have a reduced islet survival,
not suitable for long-term function [70], while the long-term
normoglycemia that we observed highlights a fully revasculariza-
tion and a complete functionality of engrafted islets even when a
marginal mass was used. A limit of our study is the assessment of
pancreatic islet transplant only in a syngenic rat model to avoid an
immunologic response due to donor-recipient immunologic
systems. This needs certainly to be further investigated in the
next future in an allogeneic co-transplant model, also by exploiting
other cell lines like Sertoli cells which appeared to maintain the
immunosuppressive effect during vascularization process [71] or
either protocols of immunosuppression [72]. This could overcome
obstacles deriving from the host’s immune rejection and impair-
ment of vascularization network in the long term. An interesting
issue on the mechanism of islet revascularization involves the
emerging measurements of vessel parameters within the endothe-
lial lumen. As reported by Alberts et al., the endothelial cells not
only repair and renew the lining of established blood vessels, but
also create new blood vessels and have a remarkable capacity to
adjust their number and arrangement to suit local requirements
[73]. By signaling to the surrounding cells, endothelial cells enable
the blood vessel to adapt its diameter and wall thickness to suit the
blood flow needed. They can be roused to proliferate with a
doubling time of just a few days [73], including variations of
thickness as it occurs in the allogeneic portal vein transplants, that
developed a significant increase in wall thickness [74]. Recently
several studies of co-transplant of pancreatic islets and EPCs
reported conflicting results about the effect of EPCs on vascular
density and their role in the mechanism of improvement in
vascularization process [27,57]. Our results demonstrated that
EPCs were able to increase the vascular density and the
endothelial thickness in co-transplant model during the first 30
days after transplantation. Subsequently a decrease of both
parameters was observed up to levels comparable with healthy
control values. This effect can be attributed to the endothelium
transition from a juvenile to a mature status. It is worthy of note
that few data is present in the literature about endothelial thickness
which for the first time was analyzed in a study about the
revascularization process. In conclusion, we provide evidence that
co-transplantation of EPCs and a marginal mass of pancreatic
islets in portal vein induce a stable rescue of glycemic control
lasting for a significant fraction of the animal life span. We show
that the glycemic control recovery is associated with EPC-induced
neovascularization, which is followed by a stabilization of islet
vascular network within a few weeks after transplantation. This is
paralleled by a down-regulation of specific genes, such as ANG-1,
involved in the vascularization process, and PECAM-1 related to
the inflammation process. This provides the experimental
evidence for the previously hypothesized revascularization process
as a key factor for successful islet transplantation. The present
results pave the way to translational experimental testing in
humans as a new therapeutic approach to overcome some
problems encountered in the search for a successful and long-
lasting surgical approach for the cure of IDDM.
Supporting Information
Figure S1 Time lapse of EPCs/GFP+ EPCs onto BD
Matrigel Basement. (A, B, C) EPCs shown an excellent ability
to form a capillary-like structure (respectively, 8 hours, 12 hours,
20 hours). (D, E, F) Bright field images of GFP+ EPCs and (G, H,
I) fluorescence images show that GFP+ EPCs grow gradually from
a sparsely scattered capillary structure (2 hours after seeding, D–
G) to a more organized (4 hours after seeding, E–H) and finally to
a complete capillary network (6 hours after seeding, F–I).
(TIF)
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